Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Novel therapeutics recognize sugar coat of the hospital germ C. difficile

19.04.2016

Now, scientists at the Max Planck Institute of Colloids and Interfaces in Potsdam have demonstrated that C. difficile bacteria can be recognized by specific sugars on their surface. Antibodies that attack the sugars can be used to treat infected animals and save their lives. The bacterium Clostridium difficile invades up to 40% of patients in hospitals, causes serious infections that require harsh treatment with antibiotics and kills about 15.000 people in Europe annually. The results reported recently in the journal Nature Communications are the basis for further clinical development.

Hospital-acquired infections are a rapidly increasing problem in industrialized countries as more antibiotic-resistant bacteria evolve. The anaerobic bacterium Clostridium difficile has emerged as a major cause of disease in hospitals and long-term care facilities where up to 40% of inpatients are infected.


Sweet target of therapeutic antibodies: the sugar molecule „PS-I“ of C. difficile is shown in its three-dimensional shape (orange: carbon; red: oxygen; white: hydrogen).

© MPI of Colloids and Interfaces

The bacterium blooms in the gut when protective bacteria are diminished by antibiotics. Symptoms include diarrhea, dehydration, intestinal inflammation and death in severe cases.

As antibiotic resistance continues to rise, novel therapies are needed urgently. In the US alone, over 250.000 C. difficile infections annually are responsible for at least 15.000 deaths and medical expenses of over one billion dollars.

Researchers at the Max Planck Institute of Colloids and Interfaces now report monoclonal antibodies against the sugars on the surface of C. difficile as a novel antibacterial therapy. Chemically synthesized sugars that resemble those covering the bacterium were used to generate monoclonal antibodies that specifically recognize and kill any pathogen carrying the motif.

Since the sugar motif called PS-I is found on a wide range of C. difficile strains, the novel therapeutic is expected to be very broadly applicable. Another advantage is that other bacteria of the gut remain intact and lower the likelihood of re-infection by C. difficile that is a common result of antibiotic treatment.

The results reported in Nature Communications are the basis for ongoing efforts to develop novel therapeutics. “This is a great example how basic research on fundamental aspects of the human immune response results in therapeutic candidates that will help fight one of the most devastating hospital-acquired infections” says Prof. Peter Seeberger, the senior author of the study.

The team at the Max Planck Institute of Colloids and Interfaces in Potsdam continues to work with Vaxxilon AG (Reinach, Switzerland) to advance novel carbohydrate vaccines. Vaxxilon has licensed certain intellectual property rights to a portfolio of vaccine candidates targeting multiple infectious agents, including C. difficile.

Weitere Informationen:

http://www.mpikg.mpg.de/cdifficile/en

Katja Schulze | Max-Planck-Institut für Kolloid- und Grenzflächenforschung

More articles from Life Sciences:

nachricht The balancing act: An enzyme that links endocytosis to membrane recycling
07.12.2016 | National Centre for Biological Sciences

nachricht Transforming plant cells from generalists to specialists
07.12.2016 | Duke University

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

NTU scientists build new ultrasound device using 3-D printing technology

07.12.2016 | Health and Medicine

The balancing act: An enzyme that links endocytosis to membrane recycling

07.12.2016 | Life Sciences

How to turn white fat brown

07.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>